- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00367237
Remicade Study in Psoriatic Arthritis Patients Of Methotrexate-Naïve Disease (RESPOND) (Study P04422)
A Randomized, Multicenter, International, Open-label Study of Infliximab Plus Methotrexate Versus Methotrexate (MTX) Alone for the Treatment of MTX naïve Subjects With Active Psoriatic Arthritis
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Phase 3
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- The subject must meet ALL of the criteria listed below for entry into the study:
- Subject must demonstrate their willingness to participate in the study and comply with its procedures by signing a written informed consent.
- Subject aged 18 years or more, of either sex and any race
Diagnosis of Psoriatic Arthritis with peripheral polyarticular involvement. Patients will have at least one of the following:
- Distal Interphalangeal Joints (DIP) involvement
- polyarticular arthritis, absence of rheumatoid nodules and presence of psoriasis
- arthritis mutilans
- asymmetric peripheral arthritis
- Negative rheumatoid factor
- The disease should have been diagnosed at least 3 months prior to screening.
Active disease at the time of screening and prior to receiving the baseline study medication(s) as defined by:
- 5 or more swollen joints and
- 5 or more tender joints
and one out of the following three categories:
- Erythrocyte Sedimentation Rate (ESR) >= 28 mm/h
- C-reactive protein (CRP) >= 15 mg/l
- Morning stiffness >= 45 min
- Subjects must confirm that they are practicing adequate contraception: Female subjects of childbearing potential (includes women who are less than 1 year postmenopausal and women who become sexually active during the study) must agree to use a medically accepted method of contraception or be surgically sterilized prior to screening, while receiving protocol-specified medication, and for 6 months after stopping the medication. Acceptable methods of contraception include condoms (male and female) with or without a spermicidal agent, diaphragm or cervical cap with spermicide, medically prescribed intrauterine device (IUD), oral or injectable hormonal contraceptive, and surgical sterilization (e.g., hysterectomy or tubal ligation).
- Female subjects of childbearing potential must have a negative pregnancy test at Screening.
- Subjects must be eligible for anti-tumor necrosis factor (TNF) treatment according to applicable local guidelines. For all patients chest X-ray and skin test results must be available at baseline.
- If using Nonsteroidal anti-inflammatory drugs (NSAIDs) or corticosteroids other than i.v., i.m. or i.a., the patient must be on a stable dose for four weeks prior screening (maximum dose up to 10mg/day of prednisone or its oral equivalent).
The screening laboratory tests must beet the following criteria:
- Hemoglobin >= 10 g/dl providing the low hemoglobin level is not due to other diseases than anemia of chronic inflammation.
- white blood cell (WBC) >= 3500 / μl
- Neutrophils >= 1500 / μl
- Platelets >= 100 000/ μl
- Aspartate aminotransferase, alanine aminotransferase, alkaline phosphatase, and gamma-glutamyltransferase <= 1.5 x upper limit of normal
- Total bilirubin <= 1 x upper limit of normal
- Serum creatinine <= 1.5 mg/dl
- Patient must be able to adhere to the study visit schedule and other protocol requirements and must have given informed consent prior to any screening procedures.
Exclusion Criteria:
- The subject will be excluded from entry into the study if ANY of the criteria listed below are met:
- Subject is a female who is pregnant, intends to become pregnant during the study (or within 6 months after study completion), or nursing.
- Patients with other inflammatory diseases that might interfere with the evaluation of the psoriatic arthritis.
- Previous treatment with Infliximab.
- Subjects who have previously received MTX or have not discontinued their other DMARD therapy (i.e., sulfasalazine, hydroxychloroquine, leflunomide).
- Patients with fibromyalgia syndrome.
- Use of cyclosporine or tacrolimus within 4 weeks prior to screening. Use of IM, IV, or IA corticosteroids within 4 weeks prior to screening.
- Treatment with any investigational drug within 3 months prior to screening.
- Previous treatment with a monoclonal antibody or a fusion protein.
- A history of known allergy to murine proteins.
- History of infected joint prosthesis within the previous 5 years.
- Chronic infections.
- History of active tuberculosis requiring treatment within previous 3 years or history of opportunistic infections within 2 months, uncontrolled active infection or documented HIV infection. Also excluded are patients with evidence of latent tuberculosis and patients with old tuberculosis without documented adequate therapy, if they will not be treated according to local tuberculosis (TB) guidelines.
- Subject has any clinically significant deviation from normal in the physical examination, chest X-ray, or electrocardiogram (ECG) that, in the investigator's judgment, may interfere with the study evaluation or affect subject safety.
- Current signs or symptoms of other severe uncontrolled diseases, which in the investigators opinion would put the patient at an unacceptable risk.
- History of lymphoproliferative disease, any current malignancies or history of malignancy within 5 years other than successfully treated basal cell carcinoma or squamous cell carcinoma of the skin.
- Subject is part of the staff or a family member of the staff personnel directly involved with this study.
- History of drug abuse.
- Subjects who are participating in any other clinical study.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Infliximab + methotrexate (IFX + MTX)
Remicade (infliximab [IFX]) 5 mg/kg infusions at Weeks 0, 2, 6, 14 and oral methotrexate (MTX) 15 mg/week
|
Infliximab 5 mg/kg infusion at Weeks 0, 2, 6, 14 and oral methotrexate 15 mg/week for 16 weeks.
Methotrexate dose can be increased to 20 mg/week at week 6.
Other Names:
|
Active Comparator: Methotrexate (MTX)
Oral methotrexate (MTX) 15 mg/week
|
Oral methotrexate 15 mg/week for 15 weeks.
Dose can be increased to 20 mg/week at Week 6.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Subjects Achieving ACR20 (at Least 20% Improvement in American College of Rheumatology Criteria From Baseline) at Week 16
Time Frame: between baseline and week 16
|
>=20% improvement in swollen and tender joint count AND >=20% improvement in 3 of the following: visual analog scale (VAS) assessment of pain; subject VAS global assessment of disease activity; evaluator VAS global assessment of disease activity; Health Assessment Questionnaire (HAQ) disability index; C-Reactive Protein (CRP) level.
|
between baseline and week 16
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Proportion of Subjects Achieving ACR50, ACR70, and PASI75 if Applicable
Time Frame: between baseline and week 16
|
This is not a prespecified key secondary outcome; therefore, results will not be disclosed.
|
between baseline and week 16
|
Change in Disease Activity Score, Each of the ACR20 Domains, Dactylitis, Enthesitis, Fatigue and Duration of Morning Stiffness, Erythrocyte Sedimentation Rate, and Disability Index of the Health Assessment Questionnaire (HAQ)
Time Frame: between baseline and week 16
|
This is not a prespecified key secondary outcome; therefore, results will not be disclosed.
|
between baseline and week 16
|
Adverse Events
Time Frame: between baseline and week 16
|
This is not a prespecified key secondary outcome; therefore, results will not be disclosed.
|
between baseline and week 16
|
Collaborators and Investigators
Sponsor
Collaborators
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Skin Diseases
- Joint Diseases
- Musculoskeletal Diseases
- Skin Diseases, Papulosquamous
- Spinal Diseases
- Bone Diseases
- Spondylarthropathies
- Spondylarthritis
- Spondylitis
- Psoriasis
- Arthritis
- Arthritis, Psoriatic
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Nucleic Acid Synthesis Inhibitors
- Enzyme Inhibitors
- Antirheumatic Agents
- Antimetabolites, Antineoplastic
- Antimetabolites
- Antineoplastic Agents
- Immunosuppressive Agents
- Immunologic Factors
- Gastrointestinal Agents
- Dermatologic Agents
- Reproductive Control Agents
- Abortifacient Agents, Nonsteroidal
- Abortifacient Agents
- Folic Acid Antagonists
- Methotrexate
- Infliximab
Other Study ID Numbers
- P04422
- EUDRACT #: 2005-002189-12
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf
http://engagezone.msd.com/ds_documentation.php
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Arthritis, Psoriatic
-
AmgenRecruitingActive Juvenile Psoriatic ArthritisSpain, United Kingdom, Turkey, Belgium, France, Greece, Italy, Austria, Germany, Netherlands, Poland, Portugal, Romania, Lithuania, South Africa
-
Universitätsklinikum Hamburg-EppendorfBristol-Myers Squibb; Eli Lilly and Company; UCB Pharma; Merck Sharp & Dohme LLC; AbbVi... and other collaboratorsRecruiting
-
Bristol-Myers SquibbCompletedPsoriatic Arthritis (PsA)Germany
-
Pope Research CorporationAmgenWithdrawn
-
Sun Pharmaceutical Industries LimitedActive, not recruitingActive Psoriatic ArthritisUnited States, Australia, Czechia, Germany, India, Japan, Korea, Republic of, Poland, Spain
-
AbbVieActive, not recruitingPsoriatic Arthritis (PsA)United States, Argentina, Australia, Belgium, Brazil, Canada, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Israel, Italy, Netherlands, New Zealand, Poland, Portugal, Puerto Rico, Singapore, South Africa, Spain, Sweden, United...
-
Sun Pharmaceutical Industries LimitedCompleted
-
Bristol-Myers SquibbCompletedActive Psoriatic ArthritisSpain, United States, Hungary, Germany, Poland, United Kingdom, Russian Federation, Italy, Czechia
-
Sun Pharmaceutical Industries LimitedRecruitingActive Psoriatic ArthritisUnited States, Australia, Czechia, Estonia, Korea, Republic of, Poland, Slovakia, Spain, Taiwan, Germany, Italy, India, Canada
-
Humanis Saglık Anonim SirketiCompletedPsoriasis and Psoriatic ArthritisIndia
Clinical Trials on Infliximab + methotrexate (IFX + MTX)
-
Children's Hospital of Fudan UniversityRecruitingCrohn Disease | Immunosuppression | Children, Only | InfliximabChina
-
Helsinki University Central HospitalFoundation for Paediatric Research, Finland; Päivikki and Sakari Sohlberg Foundation... and other collaboratorsCompletedJuvenile Idiopathic ArthritisFinland
-
Groupe d'Etude Therapeutique des Affections Inflammatoires...CompletedCrohn's DiseaseFrance
-
Bristol-Myers SquibbCompletedRheumatoid ArthritisSpain, United States, Argentina, Brazil, Canada, Mexico, Peru, Korea, Republic of, Sweden, Australia, Russian Federation, Poland, Puerto Rico, Czech Republic, Denmark, South Africa, Switzerland
-
Centocor Ortho Biotech Services, L.L.C.Schering-PloughCompletedCrohn DiseaseUnited States, France, United Kingdom, Germany, Spain, Belgium, Israel, Greece, Canada, Netherlands, Austria, Norway, Denmark, Sweden, Portugal
-
Sixth Affiliated Hospital, Sun Yat-sen UniversityRecruitingModerate to Severe Ulcerative ColitisChina
-
Chinese University of Hong KongCompletedAnkylosing Spondylitis
-
Shanghai Biomabs Pharmaceutical Co., Ltd.CompletedRheumatoid ArthritisChina
-
Merck Sharp & Dohme LLCCompleted
-
Children's Memorial Health Institute, PolandUnknown